

Amendments to the Specification

Please replace paragraph "0065" with the following paragraph "0065."

The term a "condition that modulates integrins or integrin receptors" refers to any condition that might accomplish integrin or integrin receptor modulation. In addition to the compounds referred to in the ~~earlier~~ previous paragraph, ~~additional~~ examples of ~~modulatory~~ compounds that may be used with modulatory compounds include amyloid beta peptide and mimetics thereof, oxidative free radicals (OH[·], O₂[·], etc.), lysosomal enzyme inhibitors (chloroquine, N-CBZ-L-phenylalanyl-L-alanine-diazomethylketone, N-CBZ-L-phenylalanyl-L-phenyl-alanine-diazomethylketone, ~~β-amyloid, and mimetics thereof~~, etc.), or inflammatory factors (TGFβ, IL-1β, LPS, *etc.*). These compounds can be used individually or in a cocktail containing a combination of more than one compound ~~or~~ in combination with the ~~above~~ modulatory compounds.